Q-omics provides the consensus-scored ZNF630 profile across patient tissues and cancer cell-line models. ZNF630 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF630 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF630 RNA expression shows 20,120 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, THCA, and UVM as cancer lineages where ZNF630 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF630 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF630 survival associations across molecular data types. ZNF630 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF630 RNA expression–survival associations across cancer types. High ZNF630 expression shows unfavorable associations in CESC, UVM, LGG and SKCM, but favorable associations in BLCA and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF630 RNA expression.
This table summarizes ZNF630 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF630. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF630 shows lower tumor expression in THCA and higher tumor expression in KIRC, BRCA, CHOL, LUAD and COAD. The THCA box plot shows higher ZNF630 RNA expression in normal versus tumor tissue (log2 FC = −1.150, t-test p < 0.001).
This table shows molecular features associated with ZNF630 in patient tissues and cancer cell lines. In patient samples, ZNF630 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF630 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
